PDCD1 and metastatic neoplasm: ICIs, such as pembrolizumab, nivolumab, and atezolizumab, enhance immune responses against tumors by targeting PD-1, PD-L1, and CTLA-4 and offer an important option for treating cancer, particularly for advanced or metastatic disease.